Lebrikizumab off-therapy remission sustained up to 38 weeks in atopic dermatitis
Lebrikizumab demonstrated off-therapy maintenance of response in an AD patient subset for at least 38 weeks post-discontinuation.
Authors
- Hany Elmaraghy (ORCID: https://orcid.org/0000-0003-3552-9345)
- Eckhard Wolf (ORCID: https://orcid.org/0000-0002-0430-9510)
- Chitra R Natalie
- Özge Uluçkan (ORCID: https://orcid.org/0000-0001-9468-1211)
- Angela J. Okragly (ORCID: https://orcid.org/0000-0002-1041-8000)
- Gaia GALLO
- Chenjia Xu (ORCID: https://orcid.org/0000-0002-0112-676X)
- María José Rueda
- Brian J. Nickoloff
- Thomas Bieber
- Johann E. Gudjonsson
- April W. Armstrong
- Jonathan I. Silverberg
- Kilian Eyerich
- Brian A. Moser
Institutions
- University of California, Los Angeles (US)
- Eli Lilly (United States) (US)
- George Washington University (US)
- University of Michigan (US)
- University Medical Center Freiburg (DE)
- United BioSource Corporation (United Kingdom) (GB)
- Michigan Medicine (US)
- TechSource (United States) (US)
- Almirall (Spain) (ES)
- University Dermatology (US)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Journal of Dermatological Treatment
- Published
- 2026-03-12
- DOI
- https://doi.org/10.1080/09546634.2026.2636417
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00